Health AI Central
Share:
Peer-Reviewed Publication
J Am Coll Surg2026August 25, 2026Journal Article

Negotiated Prices for Reconstructive Surgery Converge without Reduction in Overall Price Level after Federal Price Transparency Regulations.

Danielle H Rochlin1, Lily Boe2, Dan Snow3, Matthew Dimaano4, David Rubin4, Babak J Mehrara1, Evan Matros1, Forrest Xiao3
1. Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center.
3. Quantitative Research Group, Turquoise Health, San Diego, CA.
4. Health Outcomes and Quantitative Analytics, Department of Finance, Memorial Sloan Kettering Cancer Center, New York, NY.
PubMed DOI

Abstract

BACKGROUND: Federal price transparency regulations require disclosure of negotiated commercial prices, but whether these policies improve affordability for reconstructive surgery remains uncertain. We evaluated post-regulation changes in negotiated prices, price convergence, price variation, and overall inflation-adjusted price levels. STUDY DESIGN: Retrospective longitudinal observational study…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.